ProCE Banner Activity

Measurable Residual Disease in ALL: Proof of the Principle Transforming Care for Patients With Hematologic Malignancies

Slideset Download
In this downloadable slideset from the MRD in ALL video, Elias Jabbour, MD, Joseph D. Khoury, MD, and Aaron C. Logan, MD, PhD, provide expert perspective on incorporating MRD testing in ALL and the use of blinatumomab in MRD-positive ALL after CR to provide your patients with better outcomes.

Released: November 01, 2018

Expiration: October 31, 2019

No longer available for credit.

Share

Faculty

Elias Jabbour

Elias Jabbour, MD

Assistant Professor
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Joseph D. Khoury

Joseph D. Khoury, MD

Professor
Department of Hematology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Aaron C. Logan

Aaron C. Logan, MD, PhD

Associate Professor
Division of Hematology and Blood and Marrow Transplantation
University of California, San Francisco
San Francisco, California

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by educational grants from

Adaptive Biotechnologies

Amgen, Inc.

Partners

GRACE

ProCE Banner

Program Director Disclosure

Program Director

Elias Jabbour, MD

Assistant Professor
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Faculty Disclosure

Primary Author

Joseph D. Khoury, MD

Professor
Department of Hematology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Aaron C. Logan, MD, PhD

Associate Professor
Division of Hematology and Blood and Marrow Transplantation
University of California, San Francisco
San Francisco, California